Long-term impact on workplace status after radical prostatectomy

A recent Norwegian study has concluded that pre-surgical counseling of men electing treatment for prostate cancer by radical prostatectomy needs to include advice about risk for the possibility of post-surgical issues that may affect work status and their working life 3 years after their surgery. … READ MORE …

Second-line therapy for progressive, high-risk prostate cancer: time for a STAMPEDE-like trial?

Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …

One more reason to cut out the cigarettes

Surgeons already don’t like to operate on smokers. They don’t do as well during and after surgery as non-smokers, not least because smokers can have problems with anesthesia. Now come data suggesting that smoking during radiation therapy is a pretty lousy idea too. … READ MORE …

The PrKT03 trial of radiation + immunotherapy for localized prostate cancer

Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …

Cancer drugs that don’t extend survival

An article by John Fauber in this Sunday’s issue of the Milwaukee Journal-Sentinel has been receiving a lot of attention in the oncology news over the past 48 hours. The title of this article is “FDA approves cancer drugs without proof they’re extending lives.” … READ MORE …

Expansion of indication for enzalutamide recommended in Europe

Late last week the Committee for Medicinal Products for Human Use (CHMP) in Europe recommended expansion of the marketing authorization for enzalutamide within member states of the European Union. … READ MORE …

An update on the shortage of radium-223 (Xofigo)

On October 21, here in the USA, Bayer HealthCare Pharmaceuticals issued a Dear Healthcare Professional letter to medical professionals indicating that the company still does not know when it is likely to be able to start to re-supply this radiopharmaceutical agent for the treatment of late-stage prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,157 other followers